

REFINITIV

DELTA REPORT

10-Q

SWTX - SPRINGWORKS THERAPEUTICS,

10-Q - MARCH 31, 2024 COMPARED TO 10-Q - SEPTEMBER 30, 2023

The following comparison report has been automatically generated

TOTAL DELTAS	745
--------------	-----

 CHANGES	132
---	-----

 DELETIONS	280
---	-----

 ADDITIONS	333
---	-----

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-Q

X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2023 MARCH 31, 2024
OR

.. TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE TRANSITION PERIOD FROM _ TO _

COMMISSION FILE NUMBER 001-39044

SPRINGWORKS THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware

83-4066827

(State or other jurisdiction of
incorporation or organization)

(I.R.S. Employer
Identification No.)

100 Washington Blvd
Stamford, Connecticut

06902

(Address of principal executive offices)

(Zip Code)

(203) 883-9490

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.0001 per share	SWTX	The Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ``

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No ``

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	x	Accelerated filer	``
Non-accelerated filer	``	Smaller reporting company	``
		Emerging growth company	``

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ``

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes `` No x

The number of outstanding shares of the Registrant's Common Stock as of November 1, 2023 April 26, 2024 was 62,578,877. 74,086,425.

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q, or Quarterly Report, contains forward-looking statements that involve risks and uncertainties. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this Quarterly Report are forward-looking statements. In some cases, these forward-looking statements can be identified by the use of words such as "may", "will", "should", "expects", "intends", "plans", "anticipates", "believes", "estimates", "predicts", "potential", "continue" or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:

- our ability to commercialize OGSIVEO® (nirogacestat), including our ability to successfully establish and maintain commercial manufacturing and supply chains for OGSIVEO, and our expectations regarding the size and growth potential of the commercial markets for OGSIVEO;

- our plans to rely on the results from our potentially registrational Phase 2b clinical trial of mirdametinib for patients with neurofibromatosis type 1-associated plexiform neurofibromas, or NF1-PN, to support our rolling submission of a New Drug Application, or NDA, and timing in connection therewith, and to support a submission of a Marketing Authorization Application, or MAA, and timing in connection therewith;
- the success, cost and timing of our product development activities and clinical trials, including the timing and results of our ongoing Phase 2b clinical trial of mirdametinib in patients with NF1-associated plexiform neurofibromas (NF1-PN) and our ongoing Phase 2 trial of nirogacestat as a monotherapy in patients with recurrent ovarian granulosa cell tumors, the initiation and completion of any other clinical trials and related preparatory work, the expected timing of the availability of results of our clinical trials, and the registrational nature of the Phase 3 clinical trial of nirogacestat in patients with desmoid tumors and the potentially registrational nature of the Phase 2b clinical trial of mirdametinib in patients with NF1-PN; patients;
- the fact that topline or interim data from our clinical studies may not be predictive of the final or more detailed results of such study or the results of other ongoing or future studies;
- our ability and our partners' ability to successfully complete clinical trials of our product candidates for additional uses, and in combination with other agents;
- the potential attributes and benefits of our product candidates;
- our plans to commercialize any of our product candidates that achieve approval either alone or in partnership with others;
- our ability to obtain funding for our operations, including funding necessary to complete further development of our product candidates, and if approved, commercialization;
- the period over which we anticipate our existing cash, cash equivalents and marketable securities, will be sufficient to fund our operating expenses and capital expenditure requirements;
- the potential for our business development efforts to maximize the potential value of our portfolio;
- our ability to identify, in-license or acquire additional product candidates;
- the ability and willingness of our third-party collaborators to continue research and development activities relating to our product candidates, including those that are being developed as combination therapies;
- our ability to obtain and maintain regulatory approval for our product candidates, and any related restrictions, limitations or warnings in the label of an approved product candidate; product;
- the timing of our planned regulatory submissions and interactions, including the New Drug Application, or completion of our submission of an NDA for mirdametinib planned for submission anticipated in the first half second quarter of 2024, and the Marketing Authorisation Application our plans to submit an MAA filing for nirogacestat with mirdametinib to the European Medicines Agency, or EMA, in the European Union planned for

submission in the first second half of 2024, and the timing and outcome of decisions made by the U.S. Food and Drug Administration, or FDA, EMA, including the decision on the NDA MAA filing for nirogacestat accepted that we submitted and received validation for in February 2023 by the FDA and granted priority review, which currently has a Prescription Drug User Fee Act, or PDUFA, target action date of November 27, 2023, 2024, as well as those by other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies;

- the potential benefit of orphan drug exclusivity, Orphan Drug Designation, Fast Track Designation, and Breakthrough Therapy Designation, and Rare Pediatric Disease Designation for nirogacestat, mirdametinib and any other of our product candidates that may receive one or more of these designations;
- our ability to compete with companies currently marketing or engaged in the development of treatments for desmoid tumors, NF1-PN and other oncology and rare disease indications;
- our expectations regarding our ability to report topline data for our potentially registrational Phase 2b clinical trial of mirdametinib for patients with NF1-PN in the fourth quarter of 2023;
- our expectations regarding our ability to obtain and maintain intellectual property protection or market exclusivity for our product candidates and the duration of such protection;
- our ability and the potential to successfully manufacture our product candidates for preclinical studies, clinical trials and, if approved, for commercial use, the capacity of our current contract manufacturing organizations, or CMOs, to support clinical supply and commercial-scale production for product candidates and our potential election to pursue additional CMOs for manufacturing supplies of drug substance and finished drug product in the future;
- the size and growth potential of the markets for our product candidates, and our ability to serve those markets, either alone or in partnership with others;
- the rate and degree of market acceptance of our product candidates, if approved;
- regulatory developments in the United States and foreign countries;
- our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;
- the success of competing products that are or may become available;

- risks associated with global economic conditions, including inflation or uncertainty caused by political violence and unrest; unrest, including the ongoing global and regional conflicts;
- our ability to attract and retain key scientific, medical, commercial and management personnel;
- our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;
- our financial performance; and
- developments and projections relating to our competitors or our industry.

Any forward-looking statements in this Quarterly Report reflect our current views with respect to future events and future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those described under Part II, Item 1A, Risk Factors and elsewhere in this Quarterly Report. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

We may from time to time provide estimates, projections and other information concerning our industry, the general business environment, and the markets for certain diseases, including estimates regarding the potential size of those markets and the estimated incidence and prevalence of certain medical conditions. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties, and actual events, circumstances or numbers, including actual disease prevalence rates and market size, may differ materially from the information provided. Unless otherwise expressly stated, we obtained this industry information, business information, market data, prevalence information and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data, and similar sources, in each case, from sources we consider to be reliable, and in some cases applying our own assumptions and analysis that may, in the future, prove not to have been accurate.

SPRINGWORKS THERAPEUTICS, INC.
FORM 10-Q
FOR THE QUARTER ENDED SEPTEMBER 30, 2023 March 31, 2024
INDEX

PART I – FINANCIAL INFORMATION

<u>Item 1. Financial Statements (Unaudited)(Unaudited)</u>	5
<u>Condensed Consolidated Balance Sheets</u>	5
<u>Condensed Consolidated Statements of Operations</u>	6
<u>Condensed Consolidated Statements of Comprehensive Loss</u>	7
<u>Condensed Consolidated Statements of Stockholders' Equity</u>	8
<u>Condensed Consolidated Statements of Cash Flows</u>	9
<u>Notes to Condensed Consolidated Financial Statements</u>	10
<u>Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	17 16
<u>Item 3. Quantitative and Qualitative Disclosure About Market Risk</u>	24 23
<u>Item 4. Controls and Procedures</u>	25 23
 <u>PART II. OTHER INFORMATION</u> 	
<u>Item 1. Legal Proceedings</u>	26 24
<u>Item 1A. Risk Factors</u>	26 24
<u>Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</u>	26 24
<u>Item 3. Defaults Upon Senior Securities</u>	26 24
<u>Item 4. Mine Safety Disclosures</u>	26 24
<u>Item 5. Other Information</u>	26 24
<u>Item 6. Exhibits</u>	26 25
<u>SIGNATURES</u>	28 26

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

SpringWorks Therapeutics, Inc. Condensed Consolidated Balance Sheets(Unaudited)

	September	December		
	30,	31,		
	2023	2022		
March 31,			March 31,	December 31,
2024			2024	2023

(in thousands, except share and per-share data)	(in thousands, except share and per-share data)		
Assets	Assets		
Assets			
Assets			
Current assets:			
Current assets:			
Current assets:	Current assets:		
Cash and cash equivalents	Cash and cash equivalents	\$ 98,895	\$ 67,490
Cash and cash equivalents			
Cash and cash equivalents			
Marketable securities	Marketable securities	323,524	524,722
Accounts receivable, net			
Inventory			
Prepaid expenses and other current assets	Prepaid expenses and other current assets	9,964	7,548
Total current assets	Total current assets	432,383	599,760
Long-term marketable securities	Long-term marketable securities	—	4,794
Property and equipment, net	Property and equipment, net	20,924	13,571
Operating lease right-of-use assets	Operating lease right-of-use assets	6,465	4,698
Equity investment		3,789	4,193
Equity method investment			

Restricted cash	Restricted cash	610	578
Other assets	Other assets	3,483	2,648
Total assets	Total assets	\$ 467,654	\$ 630,242
Liabilities and Stockholders' equity	Liabilities and Stockholders' equity		
Current liabilities:	Current liabilities:		
Current liabilities:			
Current liabilities:			
Accounts payable			
Accounts payable			
Accounts payable	Accounts payable	\$ 5,546	\$ 8,010
Accrued expenses	Accrued expenses	40,332	39,242
Operating lease liabilities, current	Operating lease liabilities, current	1,161	483
Deferred revenue, current	Deferred revenue, current	3,244	3,314
Total current liabilities	Total current liabilities	50,283	51,049
Operating lease liabilities, long-term	Operating lease liabilities, long-term	6,170	4,768
Deferred revenue, long-term	Deferred revenue, long-term	16,302	16,233
Total liabilities	Total liabilities	\$ 72,755	\$ 72,050
Commitments and contingencies	Commitments and contingencies		

Commitments and contingencies

Stockholders' equity:	Stockholders' equity:		
Preferred stock, \$0.0001 par value, 10,000,000 shares authorized, no shares issued or outstanding at September 30, 2023 and December 31, 2022.	—	—	
Common stock, \$0.0001 par value, 150,000,000 shares authorized, 62,698,866 and 62,453,328 shares issued and 62,575,066 and 62,423,129 shares outstanding at September 30, 2023 and December 31, 2022, respectively.	6	6	

Preferred stock, \$0.0001 par value, 10,000,000 shares authorized, no shares issued or outstanding at March 31, 2024 and December 31, 2023.			
Preferred stock, \$0.0001 par value, 10,000,000 shares authorized, no shares issued or outstanding at March 31, 2024 and December 31, 2023.			
Preferred stock, \$0.0001 par value, 10,000,000 shares authorized, no shares issued or outstanding at March 31, 2024 and December 31, 2023.			

Common stock, \$0.0001 par value, 150,000,000 shares authorized, 74,355,487 and 73,620,361 shares issued, and 74,061,196 and 73,486,699 shares outstanding at March 31, 2024 and December 31, 2023, respectively.			
Additional paid-in capital	Additional paid-in capital	1,199,806	1,130,224
Accumulated deficit	Accumulated deficit	(800,712)	(569,930)
Treasury stock, at cost (123,800 and 30,199 shares of common stock at September 30, 2023 and December 31, 2022, respectively).		(3,888)	(1,341)
Accumulated other comprehensive loss		(313)	(767)
Treasury stock, at cost (160,629 and 133,662 shares of common stock at March 31, 2024 and December 31, 2023, respectively).			
Accumulated other comprehensive (loss) income			

Total stockholders' equity	Total stockholders' equity	394,899	558,192
Total liabilities and stockholders' equity	Total liabilities and stockholders' equity	\$ 467,654	\$ 630,242

See accompanying unaudited notes to condensed consolidated financial statements

SpringWorks Therapeutics, Inc.
Condensed Consolidated Statements of Operations (Unaudited)

		Three Months Ended September 30,		Nine Months Ended September 30,	
		Three Months Ended March 31,		Three Months Ended March 31,	
		Three Months Ended March 31,		Three Months Ended March 31,	
(in thousands, except share and per-share data)	(in thousands, except share and per-share data)	2023	2022	2023	2022
Operating expenses:					
(in thousands, except share and per-share data)					
(in thousands, except share and per-share data)					
Revenue:					
Revenue:					
Revenue:					
Product revenue, net					
Product revenue, net					
Product revenue, net					
Total revenue					
Total revenue					
Total revenue					

Operating costs and expenses:						
Operating costs and expenses:						
Operating costs and expenses:						
Cost of product revenue						
Cost of product revenue						
Cost of product revenue						
Selling, general and administrative						
Selling, general and administrative						
Selling, general and administrative						
Research and development	Research and development	\$	37,453	\$	36,067	\$ 106,835 \$ 108,194
General and administrative			46,546		35,673	137,715 94,026
Total operating expenses		\$	83,999	\$	71,740	\$ 244,550 \$ 202,220
Research and development						
Research and development						
Total operating costs and expenses						
Total operating costs and expenses						
Total operating costs and expenses						
Loss from operations	Loss from operations		(83,999)		(71,740)	(244,550) (202,220)
Interest and other income (expense):						
Other expense, net		\$	(76)	\$	(74)	\$ (373) \$ (291)
Interest income, net			5,662		912	17,344 1,482
Loss from operations						
Loss from operations						
Interest and other income:						
Interest and other income:						
Interest and other income:						

Interest and other income, net						
Interest and other income, net						
Interest and other income, net						
Total interest and other income	Total interest and other income	\$	5,586	\$	838	\$ 16,971 \$ 1,191
Equity investment loss			(1,024)		(1,486)	(3,203) (2,210)
Total interest and other income						
Total interest and other income						
Equity method investment loss						
Equity method investment loss						
Equity method investment loss						
Net loss						
Net loss						
Net loss	Net loss	\$	(79,437)	\$	(72,388)	\$ (230,782) \$ (203,239)
Net loss per share, basic and diluted	Net loss per share, basic and diluted	\$	(1.27)	\$	(1.37)	\$ (3.70) \$ (4.04)
Net loss per share, basic and diluted						
Net loss per share, basic and diluted						
Weighted average common shares outstanding, basic and diluted	Weighted average common shares outstanding, basic and diluted		62,521,772		52,900,819	62,386,496 50,298,015
Weighted average common shares outstanding, basic and diluted						
Weighted average common shares outstanding, basic and diluted						

See accompanying unaudited notes to condensed consolidated financial statements

SpringWorks Therapeutics, Inc.
Condensed Consolidated Statements of Comprehensive Loss (Unaudited)

		Three Months Ended September 30,		Nine Months Ended September 30,	
		Three Months Ended March 31,		Three Months Ended March 31,	
		Three Months Ended March 31,		Three Months Ended March 31,	
(in thousands)					
(in thousands)					
(in thousands)	(in thousands)	2023	2022	2023	2022
Net loss	Net loss	\$ (79,437)	\$ (72,388)	\$ (230,782)	\$ (203,239)
Net loss					
Net loss					
Changes in other comprehensive income:	Changes in other comprehensive income:				
Unrealized gain (loss) on marketable securities, net		39	304	454	(1,203)
Total changes in other comprehensive income		\$ 39	\$ 304	\$ 454	\$ (1,203)
Changes in other comprehensive income:					
Changes in other comprehensive income:					
Unrealized (loss) gain on marketable securities, net					
Unrealized (loss) gain on marketable securities, net					
Unrealized (loss) gain on marketable securities, net					
Total changes in other comprehensive (loss) income					
Total changes in other comprehensive (loss) income					
Total changes in other comprehensive (loss) income					

Comprehensive loss					
Comprehensive loss					
Comprehensive loss	Comprehensive loss	\$ (79,398)	\$ (72,084)	\$ (230,328)	\$ (204,442)

See accompanying unaudited notes to condensed consolidated financial statements

SpringWorks Therapeutics, Inc.
Condensed Consolidated Statements of Stockholders' Equity
(Unaudited)

	(in thousands)				Accumulated			
	Common		Treasury		Additional	Other		
					Paid-In	Comprehensive	Accumulated	
(in thousands, except share data)	Shares	Amount	Shares	Amount	Capital	Income (Loss)	Deficit	Total
Balance at June 30, 2022	49,458,602	\$ 5	22,430	\$ (1,129)	\$ 752,041	\$ (1,819)	\$ (423,364)	\$ 325,734
Stock-based compensation expense					18,518			18,518
Issuance of common stock to GSK	2,050,819	—			55,454			55,454
Issuance of common stock in private placement, net of issuance costs	8,650,520	1			216,830			216,831
Issuance of common stock under at-the-market offering, net of issuance costs	2,247,500	—			67,782			67,782
Forfeitures of restricted stock awards	(19,223)							—
Exercise of stock options	24,627				377			377
Shares of common stock used to satisfy tax withholding obligations			1,205	(212)				(212)
Other comprehensive income, net of tax						304		304
Net loss							(72,388)	(72,388)
Balance at September 30, 2022	62,412,845	\$ 6	23,635	\$ (1,341)	\$ 1,111,002	\$ (1,515)	\$ (495,752)	\$ 612,400
Balance at June 30, 2023	62,679,065	\$ 6	114,630	\$ (3,624)	\$ 1,176,686	\$ (352)	\$ (721,275)	\$ 451,441
Stock-based compensation expense					23,099			23,099
Forfeitures of restricted stock awards	(3,939)	—						—

Restricted stock units vested	17,272	—							—
Exercise of stock options	6,468	—			21				21
Shares of common stock used to satisfy tax withholding obligations			9,170	(264)					(264)
Other comprehensive income, net of tax							39		39
Net loss							(79,437)		(79,437)
Balance at September 30, 2023	62,698,866	\$ 6	123,800	\$ (3,888)	\$ 1,199,806	\$ (313)	\$ (800,712)	\$ 394,899	

Three Months Ended March 31, 2024 and March 31, 2023								
(in thousands, except share data)	Common		Treasury		Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)		Total
	Shares	Amount	Shares	Amount		Deficit		
Balance at December 31, 2022	62,453,328	\$ 6	30,199	\$ (1,341)	\$ 1,130,224	\$ (767)	\$ (569,930)	\$ 558,192
Equity-based compensation expense					23,395			23,395
Forfeitures of restricted stock awards	(1,039)	—						—
Restricted stock units vested	140,575	—						—
Exercise of stock options	30,913	—			83			83
Shares of common stock used to satisfy tax withholding obligations			70,140	(1,931)				(1,931)
Other comprehensive income, net of tax						605		605
Net Loss							(73,420)	(73,420)

Balance at March 31, 2023	<u>62,623,777</u>	<u>\$</u>	<u>6</u>	<u>100,339</u>	<u>\$</u>	<u>(3,272)</u>	<u>\$1,153,702</u>	<u>\$</u>	<u>(162)</u>	<u>\$</u>	<u>(643,350)</u>	<u>\$</u>	<u>506,924</u>
Balance at December 31, 2023	73,620,361	\$	7	133,662	\$	(4,141)	\$1,524,196	\$	1,191	\$	(895,034)	\$	626,219
Equity-based compensation expense							30,462						30,462
Forfeitures of restricted stock awards	(2,623)		—										—
Restricted stock units vested	410,752		—										—
Exercise of stock options	326,997		—				5,945						5,945
Shares of common stock used to satisfy tax withholding obligations				160,629		(6,497)							(6,497)
Other comprehensive income, net of tax									(1,304)				(1,304)
Net Loss											(87,385)		(87,385)
Balance at March 31, 2024	<u>74,355,487</u>	<u>\$</u>	<u>7</u>	<u>294,291</u>	<u>\$</u>	<u>(10,638)</u>	<u>\$1,560,603</u>	<u>\$</u>	<u>(113)</u>	<u>\$</u>	<u>(982,419)</u>	<u>\$</u>	<u>567,440</u>

(in thousands, except share data)	Common		Treasury		Additional Paid-In Capital	Accumulated		
	Shares	Amount	Shares	Amount		Other Comprehensive Income (Loss)	Accumulated Deficit	Total
Balance at December 31, 2021	49,247,985	\$ 5	—	\$ —	\$ 715,216	\$ (312)	\$ (292,513)	\$ 422,396
Stock-based compensation expense					54,041			54,041
Issuance of common stock to GSK	2,050,819	—			55,454			55,454
Issuance of common stock in private placement, net of issuance costs	8,650,520	1			216,830			216,831

Issuance of common stock under at-the-market offering, net of issuance costs	2,247,500	—			67,782			67,782
Issuance of restricted stock awards	36,625	—						—
Forfeitures of restricted stock awards	(26,806)	—						—
Restricted stock units vested	24,369	—						—
Exercise of stock options	181,833	—			1,679			1,679
Shares of common stock used to satisfy tax withholding obligations			23,635	(1,341)				(1,341)
Other comprehensive income, net of tax						(1,203)		(1,203)
Net loss							(203,239)	(203,239)
Balance at September 30, 2022	<u>62,412,845</u>	<u>\$ 6</u>	<u>23,635</u>	<u>\$ (1,341)</u>	<u>\$ 1,111,002</u>	<u>\$ (1,515)</u>	<u>\$ (495,752)</u>	<u>\$ 612,400</u>
Balance at December 31, 2022	62,453,328	\$ 6	30,199	\$ (1,341)	\$ 1,130,224	\$ (767)	\$ (569,930)	\$ 558,192
Stock-based compensation expense					69,467			69,467
Forfeitures of restricted stock awards	(15,485)	—						—
Restricted stock units vested	219,142	—						—
Exercise of stock options	41,881	—			115			115
Shares of common stock used to satisfy tax withholding obligations			93,601	(2,547)				(2,547)
Other comprehensive income, net of tax						454		454
Net loss							(230,782)	(230,782)
Balance at September 30, 2023	<u>62,698,866</u>	<u>\$ 6</u>	<u>123,800</u>	<u>\$ (3,888)</u>	<u>\$ 1,199,806</u>	<u>\$ (313)</u>	<u>\$ (800,712)</u>	<u>\$ 394,899</u>

See accompanying unaudited notes to condensed consolidated financial statements

SpringWorks Therapeutics, Inc.
Condensed Consolidated Statements of Cash Flows
(Unaudited)

Nine Months Ended September 30,				Three Months Ended March 31,		Three Months Ended March 31,	
(in thousands)	(in thousands)	2023	2022	(in thousands)	2024	2023	
Operating activities	Operating activities						
Net loss	Net loss	\$(230,782)	\$(203,239)				
Net loss							
Net loss							
Adjustments to reconcile net loss to net cash used in operating activities:	Adjustments to reconcile net loss to net cash used in operating activities:						
Depreciation expense		1,129	510				
Depreciation and amortization expense							
Depreciation and amortization expense							
Depreciation and amortization expense							
Non-cash operating lease expense	Non-cash operating lease expense	1,176	845				
Stock compensation expense		69,467	54,041				
Equity investment loss		3,203	2,210				
Equity-based compensation expense							
Equity method investment loss							

Changes in operating assets and liabilities	Changes in operating assets and liabilities		
Accounts receivable, net			
Accounts receivable, net			
Accounts receivable, net			
Inventory			
Prepaid expenses and other current assets	Prepaid expenses and other current assets	(2,416)	4,065
Other assets	Other assets	(686)	256
Accounts payable	Accounts payable	(2,261)	1,162
Accrued expenses	Accrued expenses	1,943	13,542
Lease liability	Lease liability	(863)	(301)
Deferred revenue		—	19,546
Net cash used in operating activities			
Net cash used in operating activities			
Net cash used in operating activities	Net cash used in operating activities	<u>\$(160,090)</u>	<u>\$(107,363)</u>
Investing activities	Investing activities		
Capital expenditures	Capital expenditures	(9,687)	(8,440)
Equity investments		(2,800)	(4,200)
Capital expenditures			
Capital expenditures			

Equity method investment			
Purchases of marketable securities	Purchases of marketable securities	(309,276)	(67,953)
Proceeds from sale and maturity of debt securities		515,722	220,006
Proceeds from sale and maturity of marketable securities			
Net cash provided by investing activities	Net cash provided by investing activities	\$ 193,959	\$ 139,413
Financing activities	Financing activities		
Proceeds from issuance of common stock to GSK		—	55,454
Proceeds from issuance of common stock in private placement, net of issuance costs		—	216,830
Proceeds from issuance of common stock under at-the-market offering, net of issuance costs		—	67,782
Treasury stock			
Treasury stock			
Treasury stock	Treasury stock	(2,547)	(1,341)
Proceeds from stock option exercises	Proceeds from stock option exercises	115	1,679

Net cash (used in) provided by financing activities		\$ (2,432)	\$ 340,404
Net increase in cash and cash equivalents		31,437	372,454
Net cash used in financing activities			
Net (decrease) increase in cash and cash equivalents			
Cash and cash equivalents including Restricted cash, beginning of period	Cash and cash equivalents including Restricted cash, beginning of period	68,068	104,526
Cash and cash equivalents including Restricted cash, end of period	Cash and cash equivalents including Restricted cash, end of period	\$ 99,505	\$ 476,980
Non-cash investing activities			
Right-of-use assets obtained in exchange for operating lease obligations		\$ 2,637	\$ 5,580

Non-cash investing activities

Right-of-use assets obtained in exchange for operating lease obligations	\$	—	\$	2,136
--	----	---	----	-------

See accompanying unaudited notes to condensed consolidated financial statements

SpringWorks Therapeutics, Inc. Notes to Condensed Consolidated Financial Statements (Unaudited)

1. Nature of Operations

SpringWorks Therapeutics, Inc., together with its wholly-owned subsidiaries, collectively, the Company, is a clinical-stage commercial-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The Company has a differentiated portfolio of small molecule targeted oncology assets, including one approved product and several clinical candidates, and is advancing programs in both rare tumor types as well as highly prevalent, genetically defined cancers. Two of OGSIVEO® (nirogacestat) is the programs are late-stage clinical product candidates: nirogacestat and mirdametinib. In December 2022, Company's first commercial product. OGSIVEO was approved by the Company submitted a New Drug Application, or NDA, to the U.S. United States Food and Drug Administration, or FDA, for nirogacestat on November 27, 2023 for the treatment of adults adult patients with progressing desmoid tumors. In February 2023, the NDA filing was accepted by the FDA and granted priority review with an assigned Prescription Drug User Fee Act, or PDUFA, target action date of August 27, 2023. On June 2, 2023, the FDA notified the Company that it had updated the PDUFA action date for the NDA by the standard extension period of three months to allow more time to review additional analyses of previously submitted data that had been provided by the Company in response to the FDA's information requests. The updated PDUFA action date for the NDA is November 27, 2023. tumors who require systemic treatment.

The Company has incurred losses and negative operating cash flows since inception and had an accumulated deficit of \$800.7 million \$982.4 million and \$569.9 million \$895.0 million, and working capital of \$382.1 million \$402.9 million and \$548.7 million \$422.7 million, as of September 30, 2023 March 31, 2024 and December 31, 2022 December 31, 2023, respectively. The Company is subject to those risks associated with any biopharmaceutical company that has substantial expenditures for development. There can be no assurance that the Company's development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, December 2023, the Company operates began to generate revenue from sales of OGSIVEO in an environment the United States. For the three months ended March 31, 2024, the Company recorded net revenue of rapid technological change and is largely dependent on \$21.0 million from the services sales of its employees, advisors, consultants and vendors. OGSIVEO.

The Company had cash, cash equivalents and marketable securities of \$422.4 million, \$573.0 million and \$597.0 million, \$662.6 million as of September 30, 2023, March 31, 2024 and December 31, 2022, December 31, 2023, respectively. Based on the Company's cash, cash equivalents and marketable securities as of September 30, 2023, March 31, 2024, management estimates that its current liquidity will enable it to meet operating expenses through at least twelve months after the date that these financial statements are issued.

2. Basis of Presentation

The Company's unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or U.S. GAAP, for interim financial information and Article 10 of Regulation S-X of the Securities and Exchange Commission, or SEC, and should be read in conjunction with the Company's consolidated financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2022, December 31, 2023, filed with the SEC on February 28, 2023, February 27, 2024. The condensed consolidated financial statements presented in this Quarterly Report on Form 10-Q are unaudited; however, in the opinion of management, such financial statements reflect all adjustments, consisting solely of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods presented.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, research and development expenses, and the valuation of stock-based equity-based compensation awards, awards and variable consideration and other relevant inputs impacting the gross and net revenue recognition. Management bases its estimates on historical experience, known trends and other market-specific or relevant factors that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions. On an ongoing basis, management evaluates its estimates, and adjusts those estimates and assumptions when facts or circumstances change. Changes in estimates are recorded in the period in which they become known.

Research and Development Expenses Summary of Significant Accounting Policies

In accordance with ASC 730, "Research and Development", expenditures for clinical development, including upfront licensing fees and milestone payments associated with products that have not yet been approved by the FDA, The Company's significant accounting policies are charged to research and development expense as incurred. These expenses consist of expenses incurred described in performing development activities, including salaries and benefits, stock-based compensation expense, preclinical expenses, clinical trial and related clinical manufacturing expenses, contract services and other outside expenses. Expenses incurred for certain research and development activities, including expenses associated with particular activities performed by contract research organizations, investigative sites in connection with clinical trials and contract manufacturing organizations, are recognized based on an evaluation of the progress or completion of specific tasks using either time-based measures or data such as information provided Note 3 to the Company by Company's audited consolidated financial statements included in its vendors Annual Report on actual activities completed or costs incurred. Payments Form 10-K for these activities are based the fiscal year ended December 31, 2023, filed with the SEC on the terms of the individual arrangements, which may differ from the pattern of expense recognition. Expenses for research and development activities incurred that February 27, 2024. There have yet to be invoiced by the vendors that perform the related activities are recorded as accrued research and development expenses. Advance payments for goods or services to be received been no significant changes in the

future Company's significant accounting policies from those disclosed in its Annual Report on Form 10-K for research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or fiscal year ended December 31, 2023, filed with the services are performed. SEC on February 27, 2024.

Recently Adopted Accounting Pronouncements

There were no recently adopted accounting pronouncements that had a material impact on the Company's financial statements, and no recently issued accounting pronouncements that are expected to have a material impact on the Company's financial statements.

3. Marketable Securities

The following table summarizes the Company's available-for-sale marketable securities as of September 30, 2023 March 31, 2024 and December 31, 2022 December 31, 2023:

As of September 30, 2023										
										As of March 31, 2024
As of March 31, 2024										
(in thousands)	(in thousands)	Gross		Gross		(in thousands)	Gross		Gross	
		Amortized	Unrealized	Unrealized	Estimated		Amortized	Unrealized	Unrealized	Estimated
		Cost	Gains	Losses	Fair Value		Cost	Gains	Losses	Fair Value
Marketable securities:	Marketable securities:									
Short-term investments:	Short-term investments:									
Short-term investments:										
Short-term investments:										
U.S. government securities										
U.S. government securities										
U.S. government securities										
Corporate debt securities										
Corporate debt securities										
Corporate debt securities										
Commercial paper										

Long-term investments:										
U.S. government securities										
U.S. government securities										
U.S. government securities	U.S. government securities	\$253,039	\$ —	\$ (297)	\$252,742					
Corporate debt securities	Corporate debt securities	14,926	—	(16)	14,910					
Commercial paper		55,872	—	—	55,872					
Total	Total	\$323,837	\$ —	\$ (313)	\$323,524					
As of December 31, 2022										
As of December 31, 2023										
As of December 31, 2023										
		Gross Amortized	Gross Unrealized Gains	Gross Unrealized Losses	Estimated Fair Value		Gross Amortized	Gross Unrealized Gains	Gross Unrealized Losses	Estimated Fair Value
(in thousands)	(in thousands)	Cost			(in thousands)	Cost				
Marketable securities:	Marketable securities:									
Short-term investments:	Short-term investments:									
Short-term investments:										
Short-term investments:										
U.S. government securities	U.S. government securities	\$232,229	\$ —	\$ (690)	\$231,539					
Non-U.S. government securities		9,388	—	(31)	9,357					
U.S. government securities										
U.S. government securities										
Corporate debt securities	Corporate debt securities	45,710	—	(44)	45,666					

Commercial paper	Commercial paper	238,160	—	—	238,160
Long-term investments:	Long-term investments:				
	U.S. government securities				
	U.S. government securities				
	U.S. government securities				
Corporate debt securities	Corporate debt securities	4,796	—	(2)	4,794
Total	Total	\$530,283	\$ —	\$ (767)	\$529,516

The Company's marketable securities are available-for-sale securities and consist of high-quality, highly liquid debt securities including corporate debt securities, U.S. government securities, non-U.S. government securities, and commercial paper.

The Company's securities classified as short-term marketable securities mature within one year or less of the balance sheet date. Marketable securities that mature greater than one year from the balance sheet date are classified as long-term. As of **September 30, 2023** **March 31, 2024**, the Company did not hold any investments with maturity dates greater than five years.

As of, and for the three **and nine** months ended **September 30, 2023** **March 31, 2024**, the Company did not have any allowance for credit losses or impairments of its marketable securities.

4. Fair Value Measurements

The fair value of the Company's financial assets measured on a recurring basis are classified based upon a fair value hierarchy consisting of the following three levels:

Level 1 — Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets, or liabilities.

Level 2 — Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the instrument.

Level 3 — Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

As of September 30, 2023, March 31, 2024 and December 31, 2023, the Company's financial assets and liabilities measured at fair value on a recurring basis consisted of the following:

U.S. government securities

U.S. government securities

Corporate debt securities						
Corporate debt securities						
Corporate debt securities	Corporate debt securities	14,909	—	14,909	—	
Commercial paper	Commercial paper	55,872	—	55,872	—	
Long-term investments:						
U.S. government securities						
U.S. government securities						
U.S. government securities						
Corporate debt securities						
Total	Total	\$347,435	\$276,654	\$70,781	\$—	
As of December 31, 2022						
Fair Value Hierarchy						
As of December 31, 2023						
As of December 31, 2023						
Fair Value Hierarchy						
(in thousands)	(in thousands)	Total	Level 1	Level 2	Level 3	(in thousands)
Financial instruments carried at fair value (asset position):						
Cash equivalents:						
Cash equivalents:						
Cash equivalents:	Cash equivalents:					
Money market funds	Money market funds	\$22,494	\$22,494	\$—	\$—	
Money market funds						

Money market funds					
Commercial paper					
Short-term investments:	Short-term investments:				
U.S. government securities	U.S. government securities	231,539	231,539	—	—
Non-U.S. government securities		9,357	—	9,357	—
U.S. government securities					
U.S. government securities					
Corporate debt securities					
Corporate debt securities					
Corporate debt securities	Corporate debt securities	45,666	—	45,666	—
Commercial paper	Commercial paper	238,160	—	238,160	—
Long-term investments:	Long-term investments:				
U.S. government securities					
U.S. government securities					
U.S. government securities					
Corporate debt securities	Corporate debt securities	4,794	—	4,794	—
Total	Total	\$552,010	\$254,033	\$297,977	\$ —

As of **September 30, 2023** **March 31, 2024** and **December 31, 2022** **December 31, 2023**, the Company's financial assets measured at fair value on a recurring basis using a market approach included cash equivalents, which consist of money market funds, and marketable securities, which consist of high-quality, highly liquid available-for-sale debt securities including corporate debt securities, U.S. government securities, non-U.S. government securities, and commercial paper.

The Company's money market funds are readily convertible into cash and the net asset value of each fund on the last day of the quarter is used to determine fair value. The U.S. government securities are classified as Level 1 and valued

utilizing quoted market prices. The Company's corporate debt securities, non-U.S. government securities, and commercial paper are classified as Level 2 and valued utilizing various market and industry inputs.

The Company considers all highly liquid instruments that have maturities of three months or less when acquired to be cash equivalents. The carrying amounts for cash equivalents, accounts payable, and accrued expenses approximate fair value due to their short-term maturities.

5. Collaboration, Licensing and Variable Interest Entities

MapKure

In June 2019, the Company announced the formation of MapKure LLC, or MapKure, an entity jointly owned by the Company and BeiGene Ltd., or BeiGene. BeiGene licensed to MapKure exclusive rights to brimarafenib (BGB-3245), an investigational oral, small molecule selective inhibitor of specific BRAF driver mutations and genetic fusions. MapKure is advancing brimarafenib through clinical development for solid tumor patients harboring BRAF driver mutations and genetic fusions that were observed to be sensitive to the compound in preclinical studies. In addition to the Company's equity ownership in MapKure, the Company maintains a member on each of MapKure's joint steering committee and board of directors. The Company also contributes to clinical development and other operational activities for brimarafenib through a service agreement with MapKure.

In conjunction with the formation of MapKure in June 2019, the Company purchased 3,500,000 Series A preferred units of MapKure, or a 25.0% ownership interest, for \$3.5 million and in June 2020, the Company purchased an additional 3,500,000 Series A preferred units of MapKure for \$3.5 million, increasing its ownership interest to 38.9%, as required by the terms of the Series A unit purchase agreement.

In June 2022, the Company made an additional investment in MapKure and purchased 4,200,000 Series B preferred units of MapKure for \$4.2 million, pursuant to the terms of a Series B preferred unit purchase agreement. In January 2023, pursuant to terms of the Series B preferred unit purchase agreement, the Company purchased an additional 2,800,000 Series B preferred units of MapKure for \$2.8 million. The ownership interest remained at 38.9%, as required by the terms of the Series B unit purchase agreement.

In January 2024, the Company made an additional investment in MapKure and purchased 8,235,200 Series C preferred units of MapKure for \$8.2 million, pursuant to the terms of a Series C preferred unit purchase agreement. The Company is required to make subsequent purchases at each of the second and third closings established by such agreement, in each case for an additional 6,176,400 Series C preferred units of MapKure for \$6.2 million. As of September 30, 2023 March 31, 2024, the Company's ownership interest in MapKure was 38.9% 39.7%.

The Company determined that MapKure is a variable interest entity. The Company is not the primary beneficiary, as the Company does not have the power to direct the activities that most significantly impact the economic performance of MapKure. Accordingly, the Company does not consolidate the financial statements of this entity and accounts for this investment using the equity method of accounting based on a one quarter lag.

The Company recognized an equity loss of \$1.0 million and \$3.2 million \$1.3 million for the three three-month periods ended March 31, 2024 and nine months ended September 30, 2023, respectively and \$1.5 million and \$2.2 million for the three and nine months ended September 30, 2022 March 31, 2023, respectively. The Company's ownership interest in MapKure is included in Equity method investments. The balance As of March 31, 2024, the Company's investment was \$3.8 million as of September 30, 2023, representing the maximum exposure to loss as a result of the Company's involvement with MapKure. MapKure is \$21.6 million, representing the carrying value of the investment of \$9.2 million plus the unfunded obligation of \$12.4 million.

GSK Expanded Non-exclusive License and Collaboration Agreement

In September 2022, the Company announced an expansion of its ongoing, non-exclusive clinical collaboration with GSK plc, formerly GlaxoSmithKline plc, or GSK, which originally commenced in June 2019. The announcement coincided with the entry by the Company and GSK into an amended and restated collaboration and license agreement, or the GSK License Agreement, for the potential continued development and commercialization of nirogacestat in combination with either belantamab mafodotin (belamaf), GSK's antibody-drug conjugate, or ADC, targeting B-cell maturation antigen, or BCMA, or any other cytotoxic ADC targeting BCMA derived from belantamab that is controlled by GSK, either alone as a combination therapy, or together with other pharmaceutical agents.

Pursuant to the terms of the GSK License Agreement and concurrent with the execution of such agreement, the Company entered into a Stock Purchase Agreement with an affiliate of GSK, Glaxo Group Limited, or GGL, under which GGL purchased 2,050,819 shares of the Company's Common Stock, par value \$0.0001 per share, or Common Stock, in a private placement transaction for an aggregate purchase price of approximately \$75.0 million, or \$36.57 per share. The shares were sold at a 25% premium to the volume-weighted average share price of the Common Stock for a specified 30-day period prior to entering into the Stock Purchase Agreement. The fair value of the Common Stock based on the closing price of Common Stock on the day prior to the effective date of the Stock Purchase Agreement was \$55.5 million and was recorded to equity. The \$19.5 million of consideration received in excess of the fair value of the Common Stock represents consideration for the license for the potential continued development and commercialization of nirogacestat in combination with GSK compounds, together with the clinical supply of nirogacestat for future belamaf clinical trials and certain research and development costs associated with nirogacestat. The Company recorded the \$19.5 million as deferred revenue in September of 2022 and will recognize revenue as the corresponding performance obligation is satisfied in proportion to expenses incurred, including clinical supply and research and development expenses, associated with the GSK License Agreement. For the three and nine months three-month period ended September 30, 2023 March 31, 2024, the revenue related to the upfront consideration received from the GSK License Agreement was insignificant.

6. Accrued Expenses

Accrued expenses consists of the following:

		December					
		September 30,	31,				
		March					
		31,				March 31,	December 31,
(in thousands)	(in thousands)	2023	2022	(in thousands)	2024	2023	

Accrued professional fees	Accrued professional fees	\$ 1,606	\$ 1,780
Accrued compensation and benefits	Accrued compensation and benefits	17,046	19,142
Accrued research and development	Accrued research and development	13,814	12,321
Accrued other	Accrued other	7,866	5,999
Total accrued expenses	Total accrued expenses	\$ 40,332	\$39,242

7. Commitments and Contingencies

The Company enters into contracts in the normal course of business for clinical trials, preclinical studies, manufacturing and other services and products for operating purposes. These contracts generally provide for termination following a certain period after notice and therefore the Company believes that non-cancelable obligations under these agreements are not material.

Additionally, the Company has excluded milestone or royalty payments or other contractual payment obligations as the timing and amounts of such obligations are unknown or uncertain.

Leases

In October 2018, the Company entered into a lease for its corporate headquarters in Stamford, CT. In January 2022, the Company amended this lease agreement to extend the lease term through April 2028, with two five-year renewal options or one ten-year renewal option. Pursuant to the amendment, the Company is entitled to \$0.5 million in tenant allowances, which may be used to offset certain future capital expenditures, and the lease payments increase by 2.5% each year commencing December 1, 2022.

In March 2023, the Company entered into a five-year operating lease in Research Triangle Park in Durham, NC (the location of the Company's discovery lab and translational operations), with two consecutive five-year renewal options. The lease payments increase by 3.0% in each of the subsequent four years of the five-year operating lease term. Rental payments under the renewal period will be at current market rates for the premises.

In August 2018, the Company entered into a five-year operating lease in Durham, NC, for additional office space which houses various corporate functions including clinical development operations. In May 2023, the Company amended this lease agreement to extend the lease term through September 30, 2026, with two consecutive five-year renewal options. Pursuant to the amendment, the lease payments increase by 3.0% each year, commencing October 1, 2023.

As of September 30, 2023, future lease payments under non-cancelable leases with terms greater than one year are as follows:

(in thousands)	Operating Leases
2023	\$ 429
2024	1,476
2025	1,999
2026	2,002
2027 and thereafter	2,550
Total lease payments	8,456
Less: imputed interest	(1,125)
Present value of lease liabilities	\$ 7,331

Contingencies

From time to time, the Company may be involved in disputes or regulatory inquiries that arise in the ordinary course of business. When the Company determines that a loss is both probable and reasonably estimable, a liability is recorded and disclosed if the amount is material to the financial statements taken as a whole. When a material loss contingency is only reasonably possible, the Company does not record a liability, but instead discloses the nature and the amount of the claim, and an estimate of the loss or range of loss, if such an estimate can reasonably be made.

As of **September 30, 2023** **March 31, 2024**, there was no litigation or contingency with at least a reasonable possibility of a material loss.

8. **Stock-Based** **Equity-Based** Compensation

2019 Equity Incentive Plan

The Company's 2019 Stock Option and **Equity** Incentive Plan, or 2019 Equity Incentive Plan, provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock units, restricted stock awards, unrestricted stock awards and dividend equivalent rights to the Company's officers, employees, directors and other key persons (including consultants). The number of shares available for issuance under the 2019 Equity Incentive Plan is cumulatively increased each January 1, through and including January 1, 2030, by 5% of the number of shares of the **Company's common stock** **Common Stock** outstanding on the immediately preceding December 31 or such lesser number of shares as determined by the compensation committee of the **Company's Board** **Company's board** of **Directors**. **directors**.

As of **September 30, 2023** **March 31, 2024**, there were **2,632,315** **3,498,653** shares available for issuance in connection with future awards under the 2019 Equity Incentive Plan.

Stock-Based Equity-Based Awards

During the nine three months ended September 30, 2023 March 31, 2024, the Company granted 2,801,624 2,174,108 stock option awards to its officers, employees and directors under the 2019 Equity Incentive Plan.

During the nine three months ended September 30, 2023 March 31, 2024, the Company awarded 1,358,719 1,152,182 restricted stock units to its officers, employees and directors under the 2019 Equity Incentive Plan.

During the nine three months ended September 30, 2023 March 31, 2024, 80,659 55,650 restricted stock awards previously issued to employees of the Company were released, 219,142 410,752 restricted stock units vested and 41,881 326,997 stock options were exercised. As of September 30, 2023 March 31, 2024, there were 6,211,502 7,112,280 stock options vested and exercisable.

In June 2019, Performance Stock Units

On January 4, 2024, the Company's Chief Executive Officer, or CEO, received an award of 176,411 stock options, or the 2019 CEO Performance Award. During the nine months ended September 30, 2023, 11,025 options of the CEO Performance Award became exercisable upon the satisfaction of the market condition applicable to this award.

Performance Stock Units

On January 5, 2023, the CEO was granted a supplemental equity award consisting of performance-based 88,000 performance based restricted stock units or a Performance Based RSU. The Performance-Based RSU covers a (the target of 284,362 shares of the Company's common stock and vests over a four-year performance period subject but not limited to the achievement of certain regulatory milestones and the CEO's continued service with the Company. In addition, the target number of shares of the Company's common stock covered is amount) that are subject to modification (upwards or downwards) by up to 25% based upon the relative a total shareholder return, or TSR, market condition based on the Company's relative TSR percentile rank compared to companies in the NASDAQ Biotechnology Index during the performance period, and are eligible to be earned and vested from 0% to 150% of the Company's shares compared to the NASDAQ Biotech Index as of the end of the performance period. target amount.

Stock-based Equity-based compensation expense included in the condensed consolidated statements of operations for each of the periods presented is as follows:

Three Months Ended	Three Months Ended March
March 31,	31,

(in thousands)		(in thousands)		2024	2023
(in thousands)		Three Months Ended September 30,		Nine Months Ended September 30,	
		2023	2022	2023	2022
Research and development	Research and development	\$ 8,502	\$ 7,101	\$ 25,976	\$ 22,217
	General and administrative	14,597	11,417	43,491	31,824
	Total stock-based compensation expense	\$ 23,099	\$ 18,518	\$ 69,467	\$ 54,041
	Research and development				
	Research and development				
	Selling, general and administrative				
	Total equity-based compensation expense				

As of **September 30, 2023** **March 31, 2024**, the unrecognized compensation expense related to unvested stock options, restricted stock units, performance stock units and restricted stock awards was **\$133.5 million** **\$144.3 million**, **\$36.7 million** **\$63.9 million**, **\$8.0 million** and **\$4.5 million** **\$1.5 million**, respectively, which is expected to be recognized over a weighted-average remaining period of approximately **2.54** **2.67**, **2.25** years, **2.09** **1.87** years and less than one year, respectively.

As of **September 30, 2023** **March 31, 2024**, the Company had **11,540,679** **13,054,654** stock options outstanding, **1,736,109** **2,076,809** unvested restricted stock units, **372,362** unvested performance stock units and **125,615** **48,561** unvested restricted stock awards.

9. Net Loss per Share

Since the Company had a net loss in each of the periods presented, basic and diluted net loss per share are the same. The table below provides potentially dilutive securities not included in the computation of the diluted net loss per share for the periods ended **September 30, 2023** **March 31, 2024** and **September 30, 2022**, **March 31, 2023** because to do so would be anti-dilutive:

		As of September 30,	
		2023	2022

Common stock options issued and outstanding	11,540,679	9,133,738
Restricted stock units subject to future vesting	1,736,109	614,511
Restricted stock awards subject to future vesting	125,615	245,010
Total potentially dilutive securities	13,402,403	9,993,259

	As of March 31,	
	2024	2023
Common stock options issued and outstanding	13,054,654	11,619,559
Restricted stock units subject to future vesting	2,076,809	1,703,188
Performance stock units subject to future vesting	372,362	—
Restricted stock awards subject to future vesting	48,561	165,303
Total potentially dilutive securities	15,552,386	13,488,050

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of the financial condition and results of operations of SpringWorks Therapeutics, Inc. should be read in conjunction with the condensed consolidated financial statements and the related notes thereto included elsewhere in this Quarterly Report on Form 10-Q, or Quarterly Report, and our consolidated financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended **December 31, 2022** December 31, 2023, or **2022 2023** Form 10-K, filed with the Securities and Exchange Commission, or SEC, on **February 28, 2023** February 27, 2024. Unless the context otherwise requires, all references to "we," "us," "our," "SpringWorks," or the "Company" refer to SpringWorks Therapeutics, Inc., together with its subsidiaries. This discussion and analysis contains forward-looking statements based upon current expectations that involve risks and uncertainties. We caution you that forward-looking statements are not guarantees of future performance, and that our actual results of operations, financial condition and liquidity, and the developments in our business and the industry in which we operate, may differ materially from the results discussed or projected in the forward-looking statements contained in this Quarterly Report. We discuss risks and other factors that we believe could cause or contribute to these potential differences elsewhere in this Quarterly Report, including in Part II, Item 1A. "Risk Factors" and under "Special Note Regarding Forward-Looking Statements." In addition, even if our results of operations, financial condition and liquidity, and the developments in our business and the industry in which we operate are consistent with the forward-looking statements contained in this Quarterly Report, they may not be predictive of results or developments in future periods. We caution readers not to place undue reliance on any forward-looking statements made by us, which speak only as of the date they are made. We disclaim any obligation, except as specifically required by law and the rules of the SEC to publicly update or revise any such statements to reflect any change in our expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

Overview

We are a clinical-stage commercial-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. We have a differentiated portfolio of small molecule targeted oncology assets, including one approved product and several clinical candidates, and are advancing programs in both rare tumor types as well as highly prevalent, genetically defined cancers. Our strategic approach and operational excellence across research, translational science and clinical development have enabled us to successfully launch our first product, rapidly advance our two lead additional product candidates into late-stage clinical trials and generate clinical data to support a regulatory filing for our lead product candidate. We have also entered into multiple shared-value partnerships with industry leaders to expand our portfolio. From this foundation, we are continuing to build a differentiated, fully-integrated, commercial biopharmaceutical company intensely focused on understanding patients and their diseases in order to develop transformative targeted medicines.

Our most advanced product candidate, nirogacestat,

OGSIVEO® (nirogacestat) is an investigational oral, small molecule gamma secretase inhibitor in development as a monotherapy for the treatment of desmoid tumors, a rare and often debilitating and disfiguring soft tissue tumor for which there are currently no therapies our first commercial product. OGSIVEO was approved by the U.S. United States Food and Drug Administration, or FDA. In December 2022, we submitted FDA, on November 27, 2023. OGSIVEO is a New Drug Application, or NDA, to novel, oral, selective gamma secretase inhibitor that is the FDA for nirogacestat for the treatment of adults with desmoid tumors. On February 27, 2023, we announced that the FDA accepted the NDA filing first and granted priority review with an assigned Prescription Drug User Fee Act, or PDUFA, target action date of August 27, 2023. On June 2, 2023, the FDA notified the Company that it had updated the PDUFA action date for the NDA by the standard extension period of three months to allow more time to review additional analyses of previously submitted data that had been provided by the Company in response to the FDA's information requests. The updated PDUFA action date for the NDA is November 27, 2023. The FDA has granted Fast Track and Breakthrough Therapy designations to nirogacestat only FDA-approved therapy for the treatment of adult patients with progressive, unresectable, recurrent or refractory progressing desmoid tumors or deep fibromatosis. Nirogacestat has also received Orphan Drug designation from who require systemic treatment.

The FDA approval of OGSIVEO was based on the FDA for the treatment of desmoid tumors and from the European Commission for the treatment of soft tissue sarcoma. The NDA submission is supported by positive data results from the Phase 3 DeFi trial, a global, randomized, double-blind, placebo-controlled trial which were published in adult patients with desmoid tumors. These positive Phase 3 data were announced in May 2022 and subsequently published in the March 9, 2023 edition of the New England Journal of Medicine, with additional data presented at various top tier scientific conferences, including the European Society for Medical Oncology Congress (ESMO) 2022, the American Society of Clinical Oncology (ASCO) Annual Meeting 2023, and the Connective Tissue Oncology Society (CTOS) Annual Meeting 2023. The Medicine. DeFi is a global, randomized (1:1), double-blind, placebo-controlled Phase 3 DeFi trial evaluating the efficacy, safety and tolerability of nirogacestat in adult patients with progressing desmoid tumors. The study randomized 142 patients to receive 150 mg of nirogacestat or placebo twice daily. OGSIVEO met its the primary endpoint of improving progression-free survival, or PFS, demonstrating a statistically significant improvement for nirogacestat over placebo, with a 71% reduction in the risk of disease progression (hazard ratio (HR) = 0.29 (95% CI: 0.15, 0.55); p< 0.001). Nirogacestat also demonstrated statistically significant Median PFS was not reached in the OGSIVEO arm and clinically meaningful improvements was 15.1 months in the placebo arm. Confirmed objective response rate, or ORR, based on RECIST v1.1 was 41% with OGSIVEO versus 8% with placebo (p<0.001); the

complete response rate was 7% in the OGSIVEO arm and 0% in the placebo arm. The median time to first response was 5.6 months with OGSIVEO and 11.1 months with placebo. PFS and ORR improvements were in favor of OGSIVEO regardless of baseline characteristics including sex, tumor location, tumor focality, treatment status, previous treatments, mutational status and history of familial adenomatous polyposis. OGSIVEO also demonstrated early and sustained improvements in patient-reported outcomes, all including pain, desmoid tumor-specific symptoms, physical/role function and overall health-related quality of which were prespecified secondary endpoints of the study. In addition, nirogacestat life. OGSIVEO exhibited a manageable safety profile in the Phase 3 DeFi trial, with 95% of all treatment-emergent and tolerability profile. The most common adverse events or TEAEs, (>15%) reported as Grade 1 or 2. The most frequently reported TEAEs in participants patients receiving nirogacestat OGSIVEO were diarrhea, ovarian toxicity, rash, nausea, fatigue, stomatitis, headache, abdominal pain, cough, alopecia, upper respiratory tract infection and fatigue. Furthermore, events of dyspnea. Warnings & Precautions include diarrhea, ovarian dysfunction, which was defined by investigator-reported events of amenorrhea, premature menopause, menopause, toxicity, hepatotoxicity, non-melanoma skin cancers, electrolyte abnormalities and ovarian failure, embryo-fetal toxicity.

OGSIVEO is the first and which was observed only FDA-approved treatment indicated specifically for desmoid tumors. In December 2023, the NCCN Clinical Practice Guidelines in 75% of women of childbearing potential receiving Oncology (NCCN Guidelines®) for Soft Tissue Sarcoma V.3.2023 were updated to recommend nirogacestat resolved in 74% of the affected participants, as an NCCN Category 1, Preferred treatment option for desmoid tumors.

We are actively engaged advancing a targeted launch strategy focused on positioning OGSIVEO as the potential standard of care for adult desmoid tumor patients. For the three months ended March 31, 2024, we recorded net product revenue of \$21.0 million from sales of OGSIVEO in commercial preparations to support the U.S. launch United States. On April 4, 2024, we received FDA approval of nirogacestat, if approved, a Supplemental New Drug Application, or sNDA, providing for the treatment addition of adults two higher dosage strengths of 150 mg and 100 mg OGSIVEO tablets in new blister packaging, which have been developed to enhance patient convenience with desmoid tumors. OGSIVEO. The blister packs are expected to be on the market in mid-May 2024.

We are also expect seeking to file expand the reach of OGSIVEO to additional geographies; in February 2024, we submitted and received validation for a Marketing Authorisation Authorization Application, with or MAA, to the European Medicines Agency, or EMA. Beyond the United States and Europe, we continue to evaluate additional territories in the European Union in the first half of 2024, which to potentially commercialize OGSIVEO.

We are also evaluating nirogacestat for the treatment of ovarian granulosa cell tumors, or GCT, a subtype of ovarian cancer.

In May 2023, we announced full enrollment of the ongoing a Phase 2 trial evaluating nirogacestat as a monotherapy in adult patients with recurrent ovarian GCT. We expect to report initial data from the trial in the second half of 2024.

Our second product candidate is mirdametinib, an investigational oral, small molecule MEK inhibitor, currently in development for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, or NF1-PN, a rare tumor of the peripheral nerve sheath that causes significant pain and disfigurement. We believe that mirdametinib has the potential to offer a best-in-class profile in order to enable the long-term treatment required for this patient

population, as compared to other MEK inhibitors. The FDA has granted mirdametinib both Orphan Drug Designation and Fast Track Designation for NF1-PN, and the European Commission has granted mirdametinib Orphan Drug Designation for NF1. In November 2021, 2023, we announced full enrollment of positive topline results from the ReNeu trial, a potentially registrational Phase 2b clinical trial of mirdametinib for pediatric and adult patients with NF1-PN, NF1-PN. As of the data cutoff date of September 20, 2023, 52% (29/56) of pediatric patients and we expect 41% (24/58) of adult patients had Blinded Independent Central Review, or BICR, confirmed objective responses within the 24-cycle treatment period (cycle length: 28 days). An additional pediatric patient and two additional adult patients achieved confirmed objective responses after Cycle 24 in the long-term follow up phase of the trial, where patients continue to report topline receive mirdametinib treatment. Median best percent change from baseline in target tumor volume was -42% and -41% in the pediatric and adult cohorts, respectively. As of the data for cutoff, the median duration of treatment was 22 months in both the pediatric and adult cohorts. Median duration of response was not reached in either cohort. Pediatric and adult patients in the ReNeu trial also experienced statistically significant improvements from baseline in pain, quality of life and physical function, as assessed across multiple patient-reported outcome, or PRO, tools. Mirdametinib was generally well tolerated in the fourth quarter ReNeu trial, with the majority of 2023 adverse events, or AEs, being Grade 1 or Grade 2. The most frequently reported AEs were rash, diarrhea and if these data are positive, we plan to submit an NDA vomiting in the pediatric cohort and rash, diarrhea and nausea in the adult cohort. 25% of pediatric patients and 16% of adult patients experienced a Grade 3 or higher treatment-related AE. The FDA granted mirdametinib both Orphan Drug Designation and Fast Track Designation for NF1-PN, and the European Commission granted mirdametinib to Orphan Drug Designation for NF1. In July 2023, the FDA also granted mirdametinib Rare Pediatric Disease Designation for the treatment of NF1, and as such, mirdametinib will be eligible to receive a priority review voucher, if approved. In March 2024, following the completion of our pre-NDA meeting with the FDA, we initiated a rolling NDA submission for mirdametinib in pediatric and adult patients with NF1-PN. The submission, which includes data from the ReNeu trial, is expected to be completed in the second quarter of 2024. We also expect to submit an MAA with the EMA for mirdametinib for the treatment of children and adults with NF1-PN in the first European Union in the second half of 2024.

In hematologic malignancies, we are evaluating novel combination regimens of nirogacestat alongside B-cell maturation antigen, or BCMA, directed therapies for the treatment of multiple myeloma. We have entered into several, non-exclusive clinical collaboration agreements with industry partners to evaluate nirogacestat in combination with several multiple different BCMA-directed therapies. In September 2023, Regeneron initiated Each partner is responsible for the conduct and expenses of a Phase 1b study arm evaluating clinical trial to evaluate the combination of nirogacestat with its respective BCMA agent in combination with linvoseltamab, a bispecific antibody targeting BCMA and CD3. In July 2023, the Hellenic Society of Haematology, through a co-supported collaborative study agreement with GSK and SpringWorks, initiated a Phase 1/2 study evaluating low-dose belamaf (belantamab mafodotin-blmf) and nirogacestat in combination with lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma patients. myeloma. In June 2023, updated clinical data from the GSK-sponsored Phase 1/2 trial of nirogacestat in combination with low-dose belantamab mafodotin, or belamaf, an antibody-drug conjugate targeting BCMA, and initial clinical data from the Janssen Research and Development, LLC, or Janssen, -sponsored Phase 1b clinical trial evaluating nirogacestat in combination with teclistamab, a bispecific antibody targeting BCMA and CD3, in patients with relapsed or refractory multiple myeloma were presented at the European Hematology Association (EHA) 2023 Congress. The updated clinical data from the GSK-sponsored trial, as of the December 9, 2022 data cut-off date, continued to support that combining nirogacestat with a low dose of belamaf may result in comparable efficacy to a higher monotherapy belamaf dose, while simultaneously and substantially reducing the frequency of high-grade ocular adverse events. The initial clinical data from the Janssen-sponsored trial, as of the December 16, 2022 data cut-off date, represented the first clinical data set of nirogacestat in combination with a BCMA bispecific agent, with the results

demonstrating high and deep response rates for the nirogacestat plus teclistamab combination across all dose levels assessed and an optimized safety profile with delayed administration of lower-dose nirogacestat. In addition to our industry collaborations, we are working July 2023, the Hellenic Society of Haematology, through a co-supported collaborative study agreement with the Fred Hutchinson Cancer Research Center GSK and Dana-Farber Cancer Institute to further explore nirogacestat's ability to potentiate BCMA-directed therapies as part of sponsored research agreements. SpringWorks, initiated a Phase 1/2 study evaluating low-dose belamaf and nirogacestat in combination with lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma patients. In September 2023, Regeneron initiated a Phase 1b study arm evaluating nirogacestat in combination with linvoseltamab, a bispecific antibody targeting BCMA and CD3.

In genetically defined metastatic solid tumors, our current clinical-stage efforts center on the mitogen activated protein kinase, or MAPK, pathway. We are evaluating mirdametinib for the treatment of solid tumors harboring MAPK aberrations in both monotherapy and combination approaches. In collaboration with BeiGene, Ltd., or BeiGene, we are exploring the combination of mirdametinib with BeiGene's lifirafenib (BGB-283) in NRAS mutant solid tumors. In addition, we are exploring the use of brimarafenib (BGB-3245) in a distinct set of genetically defined BRAF mutated tumors via MapKure, LLC an entity jointly owned by us and BeiGene. In February 2023, we dosed the first patient in a Phase 1/2a open-label, dose escalation and expansion trial evaluating mirdametinib in combination with brimarafenib in patients with advanced solid tumors harboring MAPK-activating mutations, and patients continue to be enrolled. In April 2023, we presented clinical data from both the ongoing Phase 1b trial evaluating mirdametinib in combination with lifirafenib in patients with advanced or refractory solid tumors with RAS mutations, RAF mutations and other MAPK pathway aberrations and the ongoing Phase 1a/1b trial evaluating brimarafenib in patients with advanced or refractory solid tumors harboring MAPK pathway aberrations at the American Association for Cancer Research, (AACR) or AACR, Annual Meeting. Meeting 2023. We also presented clinical data from the Phase 1b clinical trial evaluating mirdametinib in combination with BeiGene's RAF dimer inhibitor, lifirafenib at the AACR Annual Meeting 2023. These clinical data showed manageable safety profiles and clinical activity in various solid tumors with MAPK pathway aberrations. Dose expansion studies are currently ongoing for each program. In February 2023, the first patient was dosed in quarter of 2024, MapKure initiated a Phase 1/2a open-label, dose escalation and expansion 1b combination trial evaluating mirdametinib in combination with brimarafenib in patients with advanced solid tumors harboring MAPK mutations, and patients continue to be enrolled. In August 2023, MapKure submitted an IND application for a combination study of brimarafenib with panitumumab, a monoclonal antibody targeting Epidermal Growth Factor Receptor, or EGFR, in colorectal and pancreatic cancer patients with known MAPK pathway mutations and expects to initiate a Phase 1/2a mutations; patient dosing is currently underway. In an academic-sponsored study in the first quarter of 2024. In academic-sponsored studies supported by SpringWorks, mirdametinib is being evaluated for the treatment of low-grade gliomas in children and young adults and other advanced solid tumors harboring various MAPK-activating mutations. adults.

Furthermore, we intend to continue to build our portfolio with assets that have strong biological rationales and validated mechanisms of action, such as the TEA Domain, or TEAD, inhibitor program that we in-licensed from Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology, and the portfolio Biotechnology. We plan to initiate a

Phase 1a trial of epidermal growth factor receptor small molecule inhibitors that we in-licensed from Dana-Farber Cancer Institute. In the fourth quarter of 2022, we nominated a SW-682, our TEAD inhibitor development candidate, SW-682, and we plan to file an Investigational NDA for SW-682 in Hippo mutant solid tumors in the fourth second quarter of 2023. We 2024. Additionally, we are pursuing several discovery programs that represent potentially first-in-class and best-in-class product candidates designed to address tumors where no or limited treatment options exist.

In March 2024, following a review of the evolving competitive landscape for EGFR mutant lung cancers, we notified Dana-Farber Cancer Institute, or Dana-Farber, of our election to terminate our license agreement, pursuant to which we had in-licensed a portfolio of novel small molecule inhibitors of EGFR in preclinical development. The termination will be effective in September 2024. The decision also resulted in the termination of our sponsored research agreement with Stanford Medicine, or Stanford, which was intended to support lead optimization and translational biology efforts for the EGFR inhibitor portfolio. There will be no further investment in our EGFR program, and no further milestone payments or royalties to Dana-Farber are expected under the terms of the license agreement.

We continue to invest in our R&D infrastructure in a focused manner in order to support both our drug discovery capabilities and our translational medicine activities for development programs.

We also plan to continue using exploring shared-value partnerships to maximize the potential of our therapies to serve patients. We have invested in building leading preclinical, clinical, medical and commercial capabilities and have focused on structuring innovative partnerships that seek to align incentives and optimize business outcomes for each party involved. We believe that this approach will continue to allow us to expand our collaborative relationships with innovators, maximize the potential of our existing and future portfolio, and support the building of a scalable and sustainable business focused on the efficient advancement and commercialization of product candidates that hold the potential to transform the lives of oncology patients.

Components of our results of operations

Revenue

We have not generated any commercial In November 2023, the FDA approved OGSIVEO for the treatment of adult patients with progressing desmoid tumors who require systemic treatment. In December 2023, we began to generate revenue from sales of OGSIVEO in the sale United States. We record product revenue net of estimated discounts, chargebacks, rebates, product returns, and other gross-to-net revenue deductions.

Operating costs and expenses

Cost of Product Revenue

Our cost of product revenue includes the cost of goods sold, amortization expense for commercial milestones and royalty expense. Our cost of goods sold consists of raw materials, third-party manufacturing costs to manufacture the raw materials into finished product, freight and other costs associated with sales of commercial products. If

Selling, general and administrative expenses

Selling, general and administrative expenses consist primarily of salaries and related costs, including equity-based compensation, for personnel in executive, finance, corporate, commercial, business development and administrative

functions. Selling, general and administrative expenses also include consulting services, legal fees relating to patent and corporate matters; professional fees for accounting, auditing and tax services; insurance costs; administrative travel expenses; and facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs.

We anticipate that our development efforts for our current product candidates or additional product candidates that we may develop selling, general and administrative expenses will increase in the future are successful and can be commercialized, as we may generate revenue in increase our headcount to expand operations to support the future from product sales. We may enter into collaboration and license agreements from time to time that provide for certain payments due to us. Accordingly, we may generate revenue from such collaboration or license agreements in the future. organization, including commercialization efforts.

Operating expenses

Research and development expenses

Our research and development expenses consist of expenses incurred in connection with the development of our product candidates. These expenses include:

- employee-related expenses, which include salaries, benefits and stock-based equity-based compensation for our research and development personnel;
- fees paid to consultants for services directly related to our research and development programs;
- expenses incurred under agreements with third-party contract research organizations, investigative clinical trial sites, academic institutions and consultants that conduct research and development activities on our behalf or in collaboration with us;
- costs associated with discovery biology and medicinal chemistry efforts and with preclinical and clinical trials;
- costs associated with the manufacture of drug substance and finished drug product for preclinical testing and clinical trials;
- costs associated with technology and intellectual property licenses; and
- an allocated portion of facilities and facility-related costs, which include expenses for rent and other facility-related costs and other supplies.

External costs for research and development expenses are tracked on a program-by-program basis. Expenditures for clinical development, including upfront licensing fees and milestone payments associated with our product candidates, are charged to research and development expense as incurred. These expenses consist of expenses incurred in performing development activities, including salaries and benefits, materials and supplies, preclinical expenses, clinical trial and related clinical manufacturing expenses, depreciation of equipment, contract services and other outside expenses. Costs for certain development activities, such as manufacturing and clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using either time-based measures or data such as information provided to us by our vendors on actual activities completed or costs incurred.

We expect our research and development expenses to increase for the foreseeable future as we continue to invest in activities related to developing our product candidates and our preclinical programs, and as certain product candidates advance into later stages of development, including nirogacestat, for which we submitted an NDA is being studied in December 2022, ovarian granulosa cell tumors, and mirdametinib with the ReNeu trial. The process of conducting the necessary clinical trials to obtain regulatory approval is costly and time-consuming, and the successful development of our product candidates is highly uncertain. As a result, we are unable to determine the duration and completion costs of our research and development projects or when and to what extent we will generate revenue from the commercialization and sale of any of our product candidates.

General and administrative expenses

General and administrative expenses consist primarily of salaries and related costs, including stock-based compensation, for personnel in executive, finance, corporate, commercial, business development and administrative functions. General and administrative expenses also include: commercial readiness activities; legal fees relating to patent and corporate matters; professional fees for accounting, auditing, tax and administrative consulting services; insurance costs; administrative travel expenses; and facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs.

We anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support the continued development of our product candidates and expand operations to support the organization, including commercialization of our product candidates.

Interest and other income

Interest and other income consists primarily of interest income. Interest income consists of interest earned on our cash, cash equivalents and available-for-sale marketable securities.

Equity method investment loss

The equity method investment loss represents our share of the losses from the MapKure investment, which is accounted for using the equity method of accounting.

Results of Operations

Comparison of the three months ended September 30, 2023 March 31, 2024 and September 30, 2022 March 31, 2023

The following table summarizes our results of operations for the three months ended **September 30, 2023** **March 31, 2024** and **September 30, 2022** **March 31, 2023**:

(in thousands)	Three Months Ended September 30,		\$ Change	% Change
	2023	2022		
Operating expenses:				
Research and development	\$ 37,453	\$ 36,067	\$ 1,386	4 %
General and administrative	46,546	35,673	10,873	30 %
Total operating expenses	83,999	71,740	12,259	17 %
Loss from operations	(83,999)	(71,740)	(12,259)	17 %
Interest and other income (expense):				
Other expense, net	(76)	(74)	(2)	3 %
Interest income, net	5,662	912	4,750	521 %
Total interest and other income	5,586	838	4,748	567 %
Equity investment loss	(1,024)	(1,486)	462	(31)%
Net loss	\$ (79,437)	\$ (72,388)	\$ (7,049)	10 %

(in thousands)	Three Months Ended March 31,		\$ Change	% Change
	2024	2023		
Revenue:				
Product revenue, net	\$ 21,006	\$ —	\$ 21,006	— %
Total revenue	21,006	—	21,006	— %
Operating costs and expenses:				
Cost of product revenue	1,202	—	1,202	— %
Selling, general and administrative	60,113	44,175	15,938	36 %
Research and development	53,622	33,524	20,098	60 %
Total operating costs and expenses	114,937	77,699	37,238	48 %
Loss from operations	(93,931)	(77,699)	(16,232)	21 %
Interest and other income:				
Interest and other income, net	7,571	5,557	2,014	36 %
Total interest and other income	7,571	5,557	2,014	36 %
Equity method investment loss	(1,025)	(1,278)	253	(20)%
Net loss	\$ (87,385)	\$ (73,420)	\$ (13,965)	19 %

Research Revenue

In November 2023, the FDA approved OGSIVEO for the treatment of adult patients with progressing desmoid tumors who require systemic treatment. For the three months ended March 31, 2024, we recorded net product revenue of \$21.0 million from sales of OGSIVEO in the United States.

Selling, general and Development administrative expense

Research Selling, general and development expense was \$37.5 million administrative expenses increased by \$15.9 million to \$60.1 million for the three months ended September 30, 2023, an increase of \$1.4 million or 4% March 31, 2024 from \$36.1 million \$44.2 million for the three months ended September 30, 2022 March 31, 2023, an increase of 36%.

The increase in research and development expense was primarily attributable to an increase of \$3.2 million in internal costs driven by the growth in employee costs associated with increases in the number of personnel, including an increase in stock-based compensation expense, partially offset by a decrease of \$1.8 million in external costs related to drug manufacturing, clinical trials and other research.

General and Administrative

General and administrative expense was \$46.5 million for the three months ended September 30, 2023, an increase of \$10.9 million or 30% from \$35.7 million for the three months ended September 30, 2022.

The increase in selling, general and administrative expense expenses was largely attributable to commercial readiness activities to support supporting the U.S. launch of nirogacestat, if approved, for the treatment of adults with desmoid tumors. OGSIVEO. The increase in selling, general and administrative expense included a \$8.0 million \$10.1 million increase in internal costs and a \$2.8 million \$5.8 million increase in consulting and professional services. The increase in internal costs was attributable to the growth in employee costs associated with increases in the number of personnel, including an increase in stock-based equity-based compensation expense, driven by the growth of our commercial organization, which included our sales force, as well as establishing certain sales support, marketing, and commercialization functions. The increase in consulting and professional services was also primarily attributable to commercial readiness activities supporting the OGSIVEO launch.

Research and development expenses

Research and development expenses increased by \$20.1 million to \$53.6 million for the three months ended March 31, 2024 from \$33.5 million for the three months ended March 31, 2023, an increase of 60%.

The increase in research and development expenses was primarily attributable to an increase of \$14.1 million in external costs related to drug manufacturing, clinical trials, other research, consulting and professional services, and an

increase of \$6.0 million in internal costs driven by the growth in employee costs associated with increases in the number of personnel, including an increase in equity-based compensation expense.

We track research and development expenses on a program-by-program basis to the extent such spend is attributable to a specific program. Our research and development expenses by program for the periods presented were as we expand the capabilities of the organization. follows:

(in thousands)	Three Months Ended March 31,		\$ Change
	2024	2023	
Program specific costs:			
Nirogacestat	\$ 13,700	\$ 7,256	\$ 6,444
Mirdametinib	16,155	6,499	9,656
Other	9,583	1,987	7,596
Total program specific costs	39,438	15,742	23,696
Non-program specific costs	14,184	17,782	(3,598)
Total research and development expenses	\$ 53,622	\$ 33,524	\$ 20,098

Interest and Other Income other income

The increase in interest and other income was driven by an increase in interest income, net, for the three months ended September 30, 2023 March 31, 2024 as compared to the three months ended September 30, 2022 March 31, 2023. This increase was attributable to higher market yield and increased cash from financing activities during the year ended December 31, 2022.

Comparison of the nine months ended September 30, 2023 and September 30, 2022

The following table summarizes our results of operations for the nine months ended September 30, 2023 and September 30, 2022:

(in thousands)	Nine Months Ended September 30,		\$ Change	% Change
	2023	2022		
Operating expenses:				
Research and development	\$ 106,835	\$ 108,194	\$ (1,359)	(1)%
General and administrative	137,715	94,026	43,689	46 %
Total operating expenses	244,550	202,220	42,330	21 %
Loss from operations	(244,550)	(202,220)	(42,330)	21 %

Interest and other income (expense):				
Other expense, net	(373)	(291)	(82)	28 %
Interest income, net	17,344	1,482	15,862	1070 %
Total interest and other income	16,971	1,191	15,780	1325 %
Equity investment loss	(3,203)	(2,210)	(993)	45 %
Net loss	\$ (230,782)	\$ (203,239)	\$ (27,543)	14 %

Research and Development

Research and development expense was \$106.8 million for the nine months ended September 30, 2023, a decrease of \$1.4 million or 1% from \$108.2 million for the nine months ended September 30, 2022.

The decrease in research and development expense was primarily attributable to a decrease of \$8.3 million in external costs related to drug manufacturing, clinical trials and other research, partially offset by an increase of \$7.0 million in internal costs driven by the growth in employee costs associated with increases in the number of personnel, including an increase in stock-based compensation expense.

General and Administrative

General and administrative expense was \$137.7 million for the nine months ended September 30, 2023, an increase of \$43.7 million or 46% from \$94.0 million for the nine months ended September 30, 2022.

The increase in general and administrative expense was largely attributable to commercial readiness activities to support the U.S. launch of nirogacestat, if approved, for the treatment of adults with desmoid tumors. The increase in general and administrative expense included a \$27.6 million increase in internal costs and a \$16.1 million increase in consulting and professional services. The increase in internal costs was attributable to the growth in employee costs associated with increases in the number of personnel, including an increase in stock-based compensation expense, driven by the growth of our commercial organization, which included establishing certain sales, marketing, and commercialization functions. The increase in consulting and professional services was also primarily attributable to commercial readiness activities as we expand the capabilities of the organization.

Interest and Other Income

The increase in interest and other income was driven by an increase in interest income, net, for the nine months ended September 30, 2023 as compared to the nine months ended September 30, 2022. This increase was attributable to higher market yield and increased cash from financing activities during the year ended December 31, 2022 December 31, 2023.

Liquidity and Capital Resources

Sources of Liquidity

We have incurred operating losses and experienced negative operating cash flows since our inception and anticipate that we will continue to incur losses for at least the foreseeable future. Our net loss was \$230.8 million \$87.4 million and

\$203.2 million \$73.4 million for the nine three months ended September 30, 2023 March 31, 2024 and September 30, 2022 March 31, 2023, respectively. We had an accumulated deficit of \$800.7 million \$982.4 million and \$569.9 million \$895.0 million as of September 30, 2023 March 31, 2024 and December 31, 2022 December 31, 2023, respectively. Based on our cash, cash equivalents and marketable securities balances as of September 30, 2023 March 31, 2024, management estimates that our liquidity position will enable us to meet operating expenses through at least twelve months after the date that this Quarterly Report is filed. Our marketable securities consist of high-quality, highly liquid available-for-sale debt securities including corporate debt securities, U.S. government securities, non-U.S. government securities, and commercial paper.

Cash Flows

The following table provides information regarding our cash flows for the nine three months ended September 30, 2023 March 31, 2024 and September 30, 2022 March 31, 2023:

		Nine Months Ended September 30,		Three Months Ended March 31,		Three Months Ended March 31,	
(in thousands)	(in thousands)	2023	2022	(in thousands)	2024	2023	
Net cash used in operating activities	Net cash used in operating activities	\$(160,090)	\$(107,363)				
Net cash provided by investing activities	Net cash provided by investing activities	193,959	139,413				
Net cash (used in) provided by financing activities		(2,432)	340,404				
Net increase in cash and cash equivalents		31,437	372,454				
Net cash used in financing activities							

Net (decrease) increase in cash and cash equivalents			
Cash and cash equivalents including Restricted cash, beginning of period	Cash and cash equivalents including Restricted cash, beginning of period	68,068	104,526
Cash and cash equivalents including Restricted cash, end of period	Cash and cash equivalents including Restricted cash, end of period	\$ 99,505	\$ 476,980

Net Cash Used in Operating Activities

Net cash used in operating activities was \$160.1 million \$78.9 million for the nine three months ended September 30, 2023 March 31, 2024, which was driven by a net loss of \$230.8 million \$87.4 million and a net decrease from changes in operating assets and liabilities of \$4.3 million \$24.2 million, partially offset by stock-based equity-based compensation expense of \$69.5 million, equity investment loss of \$3.2 million, non-cash operating lease and depreciation expense of \$2.3 million \$30.5 million. Net cash used in operating activities was \$107.4 million \$61.8 million for the nine three months ended September 30, 2022 March 31, 2023, which was driven by a net loss of \$203.2 million \$73.4 million, partially offset by stock-based compensation expense of \$54.0 million, and a net increase decrease from changes in operating assets and liabilities of \$38.3 million \$13.6 million, an equity investment loss of \$2.2 million and non-cash operating lease partially offset by equity-based compensation expense of \$0.8 million \$23.4 million.

Net Cash Provided by Investing Activities

Net cash provided by investing activities for the nine three months ended September 30, 2023, which March 31, 2024 was driven by the sale and maturities of available-for-sale debt securities of \$515.7 million \$103.9 million, partially offset by purchases of available-for-sale debt securities of \$309.3 million, capital expenditures of \$9.7 million \$73.6 million

and our investment in MapKure of ~~\$2.8 million~~ \$8.2 million. Net cash provided by investing activities for the ~~nine~~ three months ended ~~September 30, 2022, which~~ March 31, 2023 was driven by the sale and maturities of available-for-sale debt securities of ~~\$220.0 million~~ \$172.5 million, partially offset by purchases of available-for-sale debt securities of ~~\$68.0 million~~ \$68.1 million, capital expenditures of ~~\$8.4 million~~ \$3.0 million and our ~~June 2022~~ investment in MapKure of ~~\$4.2 million~~ \$2.8 million.

Net Cash Used in ~~and Provided by~~ Financing Activities

Net cash used in financing activities for the ~~nine~~ three months ended ~~September 30, 2023~~ March 31, 2024 and the three months ended March 31, 2023 consisted of stock repurchased to satisfy employee tax withholding obligations ~~on upon~~ vesting of restricted stock ~~releases, awards,~~ partially offset by proceeds from stock option exercises. ~~Net cash provided by financing activities for the nine months ended September 30, 2022 of \$340.4 million was driven by proceeds from issuance of Common Stock of \$340.1 million.~~

Funding Requirements

Our primary use of cash is to fund operating expenses, including our research and development programs, as well as our commercialization activities and corporate operations. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable, accrued expenses and prepaid expenses.

Our future funding requirements will depend on many factors, including the following:

- the initiation, progress, timing, costs and results of preclinical studies and clinical trials for our product candidates;
- the cost of establishing sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval in regions where we choose to commercialize our products on our own;
- the degree of commercial success achieved following the successful completion of development and regulatory approval activities for a product candidate;
- the clinical development plans we establish for our product candidates;
- the number and characteristics of product candidates that we develop;
- the outcome, timing and cost of meeting regulatory requirements established by the FDA, the ~~European~~ ~~Medicines Agency~~ EMA and other comparable foreign regulatory authorities;
- the terms of our existing and any future license or collaboration agreements we may choose to enter into, including the amount of upfront, milestone and royalty obligations;
- the other costs associated with in-licensing new technologies, such as any increased costs of research and development and personnel;
- the cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights;
- the cost of defending intellectual property disputes, including patent infringement actions brought by third parties against us or our product candidates;

- the effect of competing technological and market developments; and
- the cost and timing of completion of commercial-scale outsourced manufacturing activities.

We **will** **may** need additional funds to meet operational needs and capital requirements for clinical trials, other research and development expenditures, commercial activities and business development efforts. Because of the numerous risks and uncertainties associated with the development and commercialization of our product candidates, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and anticipated clinical studies.

Until such time, if ever, as we can generate substantial product revenue, we expect to finance our operations through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, current ownership interests will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect rights of common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to delay, limit, reduce or terminate our research, product development or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.

Effects of Inflation

Although our operations are influenced by general economic conditions, we do not believe that inflation has had a material impact on our business, financial condition, or operating results during the periods presented.

Contractual Obligations

In October 2018, the Company entered into a lease for its corporate headquarters in Stamford, CT. In January 2022, the Company amended this lease agreement to extend the lease term through April 2028, with two five-year renewal options or one ten-year renewal option. Pursuant to the amendment, the Company is entitled to \$0.5 million in tenant allowances, which may be used to offset certain future capital expenditures, and the lease payments increase by 2.5% each year commencing December 1, 2022.

In March 2023, the Company entered into a five-year operating lease in Research Triangle Park in Durham, NC (the location of the Company's discovery lab and translational operations), with two consecutive five-year renewal options. The lease payments increase by 3.0% in each of the subsequent four years of the five-year operating lease term. Rental payments under the renewal period will be at current market rates for the premises.

In August 2018, the Company entered into a five-year operating lease in Durham, NC, for additional office space which houses various corporate functions including clinical development operations. In May 2023, the Company amended this lease agreement to extend the lease term through September 30, 2026, with two consecutive five-year renewal options. Pursuant to the amendment, the lease payments increase by 3.0% each year, commencing October 1, 2023.

As of September 30, 2023, the Company's future lease payments under non-cancelable leases with terms greater than one year are as follows:

(in thousands)	Operating Leases
2023	\$ 429
2024	1,476
2025	1,999
2026	2,002
2027 and thereafter	2,550
Total lease payments	8,456
Less: imputed interest	(1,125)
Present value of lease liabilities	\$ 7,331

During the nine three months ended September 30, 2023 March 31, 2024, there were no other material changes to our contractual obligations and commitments than from those described under the heading "Management's Discussion and Analysis of Financial Condition and Results of Operations—Contractual Obligations" in Part II Item 6. of our 2022 2023 Form 10-K.

We enter into contracts in the normal course of business for clinical trials, preclinical studies, manufacturing and other services and products for operating purposes. These contracts generally provide for termination following a certain period after notice and therefore we believe that our non-cancelable obligations under these agreements are not material.

Critical Accounting Policies and Use of Estimates

This discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts and the related disclosures in the financial statements and accompanying notes. These accounting policies involve critical accounting estimates because they are particularly dependent on estimates and assumptions made by management about matters that are uncertain at the time the accounting estimates are made. We base our estimates on historical experience, known trends and other market-specific or relevant factors that we believe to be reasonable under the circumstances, the results of which form the basis of making judgments; however, because future events and their effects cannot be determined with certainty, actual results may differ from those estimates, judgments or assumptions, and such differences could be material. On an ongoing basis, we evaluate our estimates, judgments and assumptions, and adjust those estimates, judgments and assumptions when facts or circumstances change. Changes in estimates are recorded in the period in which they become known. Although we believe that these estimates are reasonable, actual results could differ.

We describe our significant accounting policies in Note 3, Summary of Significant Accounting Policies, of the notes to the financial statements included in our 2022 2023 Form 10-K. We discuss our critical accounting estimates in Item 7, Management's Discussion and Analysis of Financial Condition and Results of Operations, in our 2022 2023 Form 10-K. There have been no changes in our significant accounting policies or critical accounting estimates during the nine three months ended September 30, 2023 March 31, 2024.

Item 3. Quantitative and Qualitative Disclosure About Market Risk

There were no material changes to our market risks from those described in Part II Item 7A. Quantitative and qualitative disclosures about market risk of in our 2022 2023 Form 10-K.

Item 4. Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, Act), as of the end of the period covered by this report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report were effective at a reasonable assurance level in ensuring that information required to be disclosed by us in reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms; and (ii) accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely discussions regarding required disclosure. We believe that a control system, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the control system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.

There have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. Other Information

Item 1. Legal Proceedings

As of the date of this Quarterly Report on Form 10-Q, we are not a party to any material legal proceedings. In the future, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. The outcome of litigation cannot be predicted with certainty and some lawsuits, claims or proceedings may be disposed of unfavorably to us, which could materially affect our financial condition or results of operations.

Item 1A. Risk Factors

In addition to the other information contained elsewhere in this report, you should carefully consider the risks and uncertainties described in our “Part I, Item 1A—Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2022 December 31, 2023, or 2022 2023 Form 10-K, filed with the Securities and Exchange Commission, or SEC, on February 28, 2023 and in Part II. Item 1A—Risk Factors” in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, or Q2 Form 10-Q, filed with the Securities and Exchange Commission on August 2, 2023 February 27, 2024, which could materially and adversely affect our business, prospects, financial condition and results of operations. New risk factors can emerge from time to time, and it is not possible to predict the impact that any factor or combination of factors may have on our business, prospects, financial condition and results of operations. The risk factors disclosure in our 2022 2023 Form 10-K and our Q2 Form 10-Q is qualified by the information that is described in this Quarterly Report on Form 10-Q. The risks described in our 2022 2023 Form 10-K and Q2 Form 10-Q are not our only risks. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or future results. Except as set forth in our Q2 Form 10-Q, there There have been no material changes in our risk factors previously disclosed in our 2022 2023 Form 10-K.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

None.

Item 5. Other Information

Rule 10b5-1 Trading Plans

During The following table shows the period covered “Rule 10b5-1 trading arrangements” and “non-Rule 10b5-1 trading arrangements” (as each term is defined in Item 408(a) of Regulation S-K) adopted by this Quarterly Report on Form 10-Q, none our directors and executive officers during the quarter ended March 31, 2024. No other directors or officers of the Company's directors or officers Company adopted, materially modified, or terminated any contract, instruction, Rule 10b5-1 trading arrangement or written plan for non-Rule 10b5-1 trading arrangements during the purchase or sale of Company securities that was quarter ended March 31, 2024.

Name and Position	Action Taken (Date of Action)	Trading Arrangement		Duration of the Trading Plan	Total Number of shares to be sold
		Rule 10b5-1*	Non-Rule 10b5-1**		
Julie Hambleton, M.D. Director	Adoption (March 1, 2024)	X		June 03, 2025	18,422
Saqib Islam, J.D. Chief Executive Officer	Adoption (February 29, 2024)	X		June 04, 2025	318,500 ⁽¹⁾
Badreddin Edris, Ph.D. Chief Operating Officer	Adoption (February 29, 2024)	X		June 04, 2025	110,000 ⁽¹⁾
Bhavesh Ashar, M.B.A. Chief Commercial Officer	Adoption (March 15, 2024)	X		June 18, 2025	168,248 ⁽¹⁾

* Intended to satisfy the affirmative defense Rule 10b5-1(c)

** Not intended to satisfy the affirmative defense conditions Rule 10b5-1(c).

(1) The actual number of Rule 10b5-1(c) shares that will be sold under the Exchange Act or any non-Rule Rule 10b5-1 trading arrangement, arrangement will be calculated at the time of vesting of the RSU, RSA or Option, as applicable, to satisfy tax withholding obligations.

Item 6. Exhibits

EXHIBIT INDEX

Exhibit Number	Description
3.1	Amended and Restated Certificate of Incorporation, as amended, of the Registrant, as currently in effect. (Incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 17, 2019).
3.2	Bylaws of the Registrant, as currently in effect. (Incorporated by reference to Exhibit 3.2 to the Registrant's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 17, 2019).
3.3	Amendment to Bylaws of the Registrant (Incorporated by reference to Exhibit 3.1 to the Registrants' Current Report on Form 8-K filed with the Securities and Exchange Commission on May 27, 2020).
4.1	Specimen Stock Certificate evidencing shares of common stock (Incorporated by reference to Exhibit 4.1 to the Registrant's Registration Statement on Form S 1/A (File No. 333 233351) filed with the

	<u>Securities and Exchange Commission on September 12, 2019).</u>
4.2	<u>Amended and Restated Investors' Rights Agreement among the Registrant and certain of its stockholders, dated August 30, 2019 (Incorporated by reference to Exhibit 4.2 to the Registrant's Registration Statement on Form S-1 (File No. 333-233351) filed with the Securities and Exchange Commission on September 12, 2019).</u>
4.3	<u>Amended Description of the Registrant's Securities (Incorporated by reference to Exhibit 4.3 to the Registrant's Annual Report on Form 10-K for the year ended December 31, 2019 December 31, 2023, filed with the Securities and Exchange Commission on March 12, 2020). February 27, 2024.)</u>
4.4	<u>Amendment to the Amended and Restated Investors' Rights Agreement, dated as of February 25, 2021 (Incorporated by Reference to Exhibit 4.4 to the Registrant's Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchanges Commission on February 25, 2021).</u>
10.1#	<u>Separation and Consulting Agreement, dated January 31, 2024, by and between L. Mary Smith and the Registrant (Incorporated by reference to Exhibit 10.1 to Registrant's Current Report on Form 8-K filed with the Securities and Exchange Commission on February 2, 2024).</u>
31.1*	<u>Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</u>
31.2*	<u>Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</u>
32.1†	<u>Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</u>
32.2†	<u>Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</u>
101.INS	Inline XBRL Instance Document.
101.SCH	Inline XBRL Taxonomy Extension Schema Document.
101.CAL	Inline XBRL Taxonomy Calculation Linkbase Document.
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104	Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)

* Filed herewith.

Indicates a management contract or any compensatory plan, contract or arrangement.

† This certification will not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section. Such certification will not be deemed to

be incorporated by reference into any filing under the Securities Act of 1933, as amended, except to the extent that the Registrant specifically incorporates it incorporated by reference. reference into such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

SPRINGWORKS THERAPEUTICS, INC.

Date: November 2, 2023 May 2, 2024

By: /s/ Saqib Islam

Saqib Islam

Chief Executive Officer

Date: November 2, 2023 May 2, 2024

By: /s/ Francis I. Perier, Jr.

Francis I. Perier, Jr.

Chief Financial Officer

28 26

Exhibit 31.1

CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

CERTIFICATIONS

I, Saqib Islam, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of SpringWorks Therapeutics, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)):

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 2, 2023 May 2, 2024

By: /s/ Saqib Islam

Saqib Islam

Chief Executive Officer

(Principal Executive Officer)

**CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES
EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY
ACT OF 2002**

CERTIFICATIONS

I, Francis I. Perier, Jr., certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of SpringWorks Therapeutics, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)):
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of

financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 2, 2023 May 2, 2024

By: /s/ Francis I. Perier, Jr.

Francis I. Perier, Jr.

Chief Financial Officer

(Principal Financial Officer)

**CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report on Form 10-Q of SpringWorks Therapeutics, Inc. (the "Company") for the period ended **September 30, 2023** **March 31, 2024**, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned, Saqib Islam, Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: **November 2, 2023** **May 2, 2024**

By: /s/ Saqib Islam

Saqib Islam

Chief Executive Officer

(Principal Executive Officer)

**CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report on Form 10-Q of SpringWorks Therapeutics, Inc. (the "Company") for the period ended **September 30, 2023** **March 31, 2024**, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned, Francis I. Perier, Jr., Chief Financial Officer of the Company, hereby certifies,

pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

- (1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 2, 2023 May 2, 2024

By: /s/ Francis I. Perier, Jr.

Francis I. Perier, Jr.
Chief Financial Officer
(Principal Financial Officer)

DISCLAIMER

THE INFORMATION CONTAINED IN THE REFINITIV CORPORATE DISCLOSURES DELTA REPORT™ IS A COMPARISON OF TWO FINANCIALS PERIODIC REPORTS. THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORT INCLUDING THE TEXT AND THE COMPARISON DATA AND TABLES. IN NO WAY DOES REFINITIV OR THE APPLICABLE COMPANY ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED IN THIS REPORT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S ACTUAL SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.

©2024, Refinitiv. All rights reserved. Patents Pending.